Adding immunotherapy to chemotherapy after surgery for stage 3 colon cancer may help decrease recurrence and death rate by 50 ...

The addition of postsurgical atezolizumab immunotherapy to standard-of-care chemotherapy in patients with stage III deficient ...

The risk of recurrence or death after surgery for deficient mismatch repair (dMMR) colon cancer decreased by 50% in patients ...

Researchers at ASCO reviewing data from the ATOMIC trial said they will change practice based on the results but questioned ...

Adding atezolizumab to chemo in stage 3 dMMR colon cancer halves the risk of recurrence, marking a major step in precision ...

Tecentriq and chemotherapy combination reduces the risk of death versus chemotherapy alone in deficient mismatch repair, ...

Adding atezolizumab to standard adjuvant chemotherapy significantly delayed recurrence or death for individuals with stage ...

Colon cancer is the third most prevalent form of cancer in the U.S., and while screening has helped detect and prevent colon ...

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...